Skip to content
Subscriber Only

Amylin, Alkermes Diabetes Drug Wins Approval on Third Try

Amylin Pharmaceuticals Inc. and Alkermes Plc succeeded in their third attempt to gain U.S. clearance for Bydureon, a once-weekly version of Amylin’s diabetes shot.

The Food and Drug Administration approved the drug for adults with Type 2 diabetes, the agency said today in a letter posted on their website.